Bausch Health Cos Inc. (NYSE:BHC) Given Average Recommendation of “Reduce” by Brokerages

Shares of Bausch Health Cos Inc. (NYSE:BHC) have earned a consensus rating of “Reduce” from the five brokerages that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and four have assigned a hold recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $8.00.

Several equities analysts have issued reports on the stock. Weiss Ratings lowered shares of Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 4th. Barclays cut their price target on shares of Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 25th. Royal Bank Of Canada cut their price target on shares of Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating on the stock in a report on Monday, April 27th. Finally, Wall Street Zen lowered shares of Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a report on Sunday, February 15th.

Insider Transactions at Bausch Health Cos

In other news, Director Frank D. Lee sold 24,456 shares of Bausch Health Cos stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $5.43, for a total transaction of $132,796.08. Following the completion of the sale, the director directly owned 49,339 shares in the company, valued at approximately $267,910.77. The trade was a 33.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 20.67% of the company’s stock.

Institutional Investors Weigh In On Bausch Health Cos

Institutional investors and hedge funds have recently made changes to their positions in the stock. Caption Management LLC lifted its stake in shares of Bausch Health Cos by 101.1% during the fourth quarter. Caption Management LLC now owns 4,464 shares of the company’s stock worth $31,000 after buying an additional 405,789 shares during the period. Caitong International Asset Management Co. Ltd lifted its stake in shares of Bausch Health Cos by 12,589.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,949 shares of the company’s stock worth $34,000 after buying an additional 4,910 shares during the period. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Bausch Health Cos by 6,661.3% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock worth $35,000 after buying an additional 5,329 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of Bausch Health Cos by 65.9% during the second quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock worth $51,000 after buying an additional 3,106 shares during the period. Finally, Camelot Portfolios LLC acquired a new stake in shares of Bausch Health Cos during the fourth quarter worth $59,000. 78.65% of the stock is currently owned by institutional investors and hedge funds.

Bausch Health Cos Price Performance

NYSE BHC opened at $5.06 on Wednesday. The firm’s fifty day simple moving average is $5.46 and its two-hundred day simple moving average is $5.99. The company has a current ratio of 1.32, a quick ratio of 0.97 and a debt-to-equity ratio of 54.68. Bausch Health Cos has a 12-month low of $4.93 and a 12-month high of $8.69. The firm has a market capitalization of $1.89 billion, a P/E ratio of -1.56 and a beta of 0.40.

Bausch Health Cos (NYSE:BHC) last released its quarterly earnings results on Wednesday, April 29th. The company reported $0.78 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.81 by ($0.03). Bausch Health Cos had a negative return on equity of 2,922.77% and a negative net margin of 11.47%.The firm had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.37 billion. Analysts forecast that Bausch Health Cos will post 4.08 EPS for the current fiscal year.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.